HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4
Open Access
- 29 April 2026
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 101
Abstract
Purpose Triple-negative breast cancer (TNBC) displays an aggressive clinicopathological profile. Despite cytotoxic chemotherapy being the primary systemic therapy, complete responses are achieved in fewer than 30% of patients, highlighting the need for new therapeutic targets and a deeper understanding of disease-driving mechanisms. Methods This study identified key oncogenic factors in TNBC through multi-omics differential analyses. Cell proliferation, migration, and invasion abilities were assessed using CCK-8, colony formation, and transwell migration and invasion assays. Quantitative proteomics was applied to profile downstream protein alterations following HDHD5 knockdown. Western blotting and RT-qPCR were used to examine expression levels in different samples. Xenograft tumor model was employed to investigate the in vivo functions of HDHD5. Results HDHD5 was highly expressed in TNBC and its elevated expression was associated with poor patient prognosis. Functional studies demonstrated that HDHD5 promotes TNBC cell proliferation and colony formation, as well as enhances cell migration and invasion. Mechanistically, HDHD5 facilitates epithelial–mesenchymal transition (EMT) associated phenotypes and promotes migratory and invasive capacities in TNBC cell lines, at least in part, through regulation of S100A4. Consistently, HDHD5 promoted TNBC tumor growth both in vitro and in vivo via S100A4. Conclusion Our study reveals HDHD5 as a previously unrecognized driver of tumor progression in TNBC and highlights its potential as a therapeutic target and prognostic biomarker for this aggressive breast cancer subtype.Keywords
This publication has 33 references indexed in Scilit:
- MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotationsNucleic Acids Research, 2020
- TIMER2.0 for analysis of tumor-infiltrating immune cellsNucleic Acids Research, 2020
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesCancer Cell, 2019
- S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in GlioblastomaCancer Research, 2017
- Metabolic reprogramming and epithelial‐to‐mesenchymal transition in cancerThe FEBS Journal, 2017
- S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast CancerCancer Research, 2017
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- Clinical management of breast cancer heterogeneityNature Reviews Clinical Oncology, 2015
- A Mitochondrial Switch Promotes Tumor MetastasisCell Reports, 2014
- Mitochondria: In Sickness and in HealthCell, 2012